Effect of Complement Consumption by Cobra Venom Factor on the Course of Primary Infection with Simian Immunodeficiency Virus in Rhesus Monkeys
- 20 January 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 15 (2) , 195-202
- https://doi.org/10.1089/088922299311619
Abstract
Cobra venom factor (CVF)-induced consumption of complement proteins was used to investigate the role of complement in vivo in the immunopathogenesis of simian immunodeficiency virus of macaques (SIVmac) infection in rhesus monkeys. Repeated administration of CVF was shown to deplete complement to < 5% of baseline hemolytic activity of serum complement for 10 days in a normal monkey. Three groups of SIVmac-infected animals were then evaluated: monkeys treated with CVF resulting in complement depletion from days - 1 to 10 postinfection, monkeys treated with CVF resulting in complement depletion from days 10 to 21 postinfection, and control monkeys that received no CVF. CD8+ SIVmac-specific cytotoxic T lymphocyte (CTL) generation and CD4+ T lymphocyte depletion during primary infection were not affected by CVF treatment. Viral load, assessed by measurements of plasma p27gag antigen and viral RNA, was transiently higher during the first 4 weeks following infection in the CVF-treated monkeys and the subsequent clinical course in these treated animals was accelerated. These results suggest that complement proteins may participate in immune defense mechanisms that decrease virus replication following the initial burst of intense viremia during primary SIVmac infection. However, we cannot rule out that the observed increased virus replication was induced by immune activation resulting from the administration of a foreign antigen to these monkeys.Keywords
This publication has 34 references indexed in Scilit:
- Antibody response to a T-dependent antigen requires B cell expression of complement receptors.The Journal of Experimental Medicine, 1996
- C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired ImmunityScience, 1996
- Elevated Levels of iC3b and C4d, but Not Bb, Complement Fragments from Plasma of Persons Infected with Human T Cell Leukemia Virus (HTLV) with HTLV-I-Associated Myelopathy/Tropical Spastic ParaparesisThe Journal of Infectious Diseases, 1995
- The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activationClinical and Experimental Immunology, 1995
- Suppression of the Immune Response by a Soluble Complement Receptor of B LymphocytesScience, 1991
- Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivityInternational Immunology, 1991
- Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.Journal of Clinical Investigation, 1986
- Does cyclosporine act in vivo as it does in vitro?Immunology Today, 1986
- IMMUNE RETENTION: IMMUNOLOGICAL REQUIREMENTS FOR MAINTAINING AN EASILY DEGRADABLE ANTIGEN IN VIVOImmunology & Cell Biology, 1979
- ROLE OF COMPLEMENT IN INDUCTION OF ANTIBODY PRODUCTION IN VIVOThe Journal of Experimental Medicine, 1974